… -valsartan, licensed for the treatment of heart failure in 2015, … In the pivotal trial, the
sacubitril-valsartan group showed a 4.7… causes or hospitalization for heart failure—after a median …

… Heart Failure) trial showed that sacubitril/valsartan reduced the relative risk of cardiovascular
mortality and heart failure … period during which sacubitril/valsartan was uptitrated to a target …

… /valsartan with enalapril in patients with chronic heart failure with reduced EF. Eligibility
requirements at screening included an age of at least 18 years, New York Heart Association …

… the introduction of sacubitril/valsartan (Entresto) in patients with heart failure (HF) and … -life
eligibility for sacubitril/valsartan in a population of patients suffering from chronic HF, regularly …

… qd use of valsartan in hypertension, no clinical studies have compared the tolerability of
this strategy with bid dosing in heart failure; however, 2 trials using valsartan 160 mg qd have …

… of heart failure in the United States: a policy statement from the American Heart Association.
… Forecasting the impact of heart failure in the United States: a policy statement from the …

… AbstrAct Exacerbation of chronic heart failure (HF) is the most common cause of … / valsartan,
a drug belonging to angiotensin receptor–neprilysin inhibitors (ARNIs). Sacubitril / valsartan …

… /valsartan in a patient treated with hemodialysis. We describe the case of a 67-year-old
man with heart failure with reduced ejection fraction due to an ischemic cardiomyopathy and …

… chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic
heart failure … Developed with the special contribution of the Heart Failure Association (HFA) of …

… Sacubitril-valsartan has been shown to have superior effects over angiotensin-converting …
with heart failure (HF) and hypertension. The efficacy and safety of sacubitril-valsartan in …